- Home
- AUUD vs TOVX Comparison
AUUD vs TOVX Comparison
Compare AUUD & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- TOVX
- Stock Information
- Founded
- AUUD 2012
- TOVX 2001
- Country
- AUUD United States
- TOVX United States
- Employees
- AUUD N/A
- TOVX N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- TOVX Health Care
- Exchange
- AUUD Nasdaq
- TOVX Nasdaq
- Market Cap
- AUUD 3.1M
- TOVX 3.5M
- IPO Year
- AUUD 2021
- TOVX 2006
- Fundamental
- Price
- AUUD $0.50
- TOVX $1.18
- Analyst Decision
- AUUD
- TOVX Strong Buy
- Analyst Count
- AUUD 0
- TOVX 1
- Target Price
- AUUD N/A
- TOVX $6.00
- AVG Volume (30 Days)
- AUUD 97.2K
- TOVX 97.3K
- Earning Date
- AUUD 11-07-2024
- TOVX 11-12-2024
- Dividend Yield
- AUUD N/A
- TOVX N/A
- EPS Growth
- AUUD N/A
- TOVX N/A
- EPS
- AUUD N/A
- TOVX N/A
- Revenue
- AUUD N/A
- TOVX N/A
- Revenue This Year
- AUUD N/A
- TOVX N/A
- Revenue Next Year
- AUUD N/A
- TOVX N/A
- P/E Ratio
- AUUD N/A
- TOVX N/A
- Revenue Growth
- AUUD N/A
- TOVX N/A
- 52 Week Low
- AUUD $0.48
- TOVX $1.14
- 52 Week High
- AUUD $11.75
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- AUUD 36.30
- TOVX 38.15
- Support Level
- AUUD $0.58
- TOVX $1.23
- Resistance Level
- AUUD $0.57
- TOVX $1.34
- Average True Range (ATR)
- AUUD 0.05
- TOVX 0.08
- MACD
- AUUD -0.01
- TOVX 0.01
- Stochastic Oscillator
- AUUD 1.18
- TOVX 12.50
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products include Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.